Should rosuvastatin be withdrawn from the market?

Stefan R Florentinus; Eibert R Heerdink; Olaf H Klungel; Anthonius de Boer

doi:10.1016/S0140-6736(04)17301-7

Should rosuvastatin be withdrawn from the market?

Stefan R Florentinus, Eibert R Heerdink, Olaf H Klungel, Anthonius de Boer

Research output: Contribution to journal › Article › Academic › peer-review

Original language	English
Pages (from-to)	1577; author reply 1578-9
Journal	The Lancet
Volume	364
Issue number	9445
DOIs	https://doi.org/10.1016/S0140-6736(04)17301-7
Publication status	Published - 3 Nov 2004

Keywords

Drug Approval
Drug Utilization
Fluorobenzenes
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Netherlands
Product Surveillance, Postmarketing
Pyrimidines
Sulfonamides

Access to Document

10.1016/S0140-6736(04)17301-7

Cite this

@article{1491e09312b748078553bc7c0b2151bb,

title = "Should rosuvastatin be withdrawn from the market?",

keywords = "Drug Approval, Drug Utilization, Fluorobenzenes, Humans, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Netherlands, Product Surveillance, Postmarketing, Pyrimidines, Sulfonamides",

author = "Florentinus, {Stefan R} and Heerdink, {Eibert R} and Klungel, {Olaf H} and {de Boer}, Anthonius",

year = "2004",

month = nov,

day = "3",

doi = "10.1016/S0140-6736(04)17301-7",

language = "English",

volume = "364",

pages = "1577; author reply 1578--9",

journal = "The Lancet",

issn = "0140-6736",